IMD 101
Alternative Names: IMD-101Latest Information Update: 20 Jul 2026
At a glance
- Originator Shanghai Affinity Biopharmaceutical
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant proteins
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Bladder cancer; Solid tumours
Most Recent Events
- 22 Apr 2026 Adverse events data from preclinical trials in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 22 Apr 2026 Interim adverse events data from a phase-I trial in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 06 Mar 2024 Phase-I clinical trials in Bladder cancer (Late-stage disease, Second-line therapy or greater) in Australia (IV) (Prior to March 2024) (ACTRN12623001217695p)